TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update following its recently announced sale of the Company’s Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP (the “Ketamine ANDA”). The transaction was a strategic sale of a single generic ketamine asset and th ...